FILTER
FILTERED INTERVIEW RESULTS
Mark A. Goldberg
CEO, ALLUCENT
"Given that a significant amount of intellectual property and cutting-edge science resides within smaller companies, we created a purpose-built firm to help smaller players develop their products and bring them to market."
Gil Roth
PRESIDENT, PBOA
"The Ukraine crisis highlighted how Europe needs to look at its energy supply and how it will make sure they have secure supply chains. Part of that has involved the US more closely. Geopolitics will have a more significant impact going forward."
Terry Myerson
CEO, TRUVETA
"Truveta Studio is the first data and analytics solution to study patient care and outcomes for all conditions, drugs, and medical devices. Pfizer is using Truveta Studio to study COVID-19."
Ajay Tandon
MANAGING DIRECTOR, VEEDA CLINICAL RESEARCH
"We now offer end-to-end modular technical services, encompassing both pre-clinical and clinical development of biosimilars addressing global regulatory requirements."
Gaurav Kaushik
MANAGING DIRECTOR AND CEO, METEORIC BIOPHARMACEUTICALS
"We are looking into new ways to reap the benefits of artificial intelligence, particularly on the clinical side. On the physical side, Meteoric Biopharmaceuticals will have a new factory and lab up and running by the end of 2024, that will work on advanced fermentation processes."
Liping Liu
FOUNDER & CEO, HIGHTIDE THERAPEUTICS
"As more robust drug candidates are emerging, I am willing to bet that we will have the first NASH drug approved in 2023."
Anwar Daud
MANAGING DIRECTOR, ZIM LABORATORIES
"ZIM sees great opportunity in improving the functioning of the overall healthcare system through providing more patient centric drug delivery systems."
Krishna Kanumuri
CEO & MANAGING DIRECTOR, SAI LIFE SCIENCES
"The biotech industry in India is currently extremely nascent, but it is evolving fast as generic margins drop, and many companies are starting to explore more innovative approaches to doing business. I anticipate Sai will take on more companies in the biotech sector in the future."
Bindi Chudgar
MANAGING DIRECTOR, LAMBDA THERAPEUTIC RESEARCH
"With our expanding global footprint, we firmly believe that we are well positioned to achieve the vision of creating benchmarks and shaping the future of the clinical research industry by ensuring quality, reliability, and value-added services.”
Karan Singh
MANAGING DIRECTOR, ACG
"Personalized medicine will disrupt the pharma industry. I also see more people looking to leverage the digitization of patient care, such as through telemedicine or the creation of wearable technologies."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Mexico Chemicals 2024
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
In August 2023, Mexican exports to the US surpassed China for the first time. As companies prioritize securing supply their chains after years of logistics challenges, Mexico has begun to see major benefits. With a spate of new infrastructure projects such as the Interoceanic Corridor of the Isthmus of Tehuantepec coming online in 2023, the country is actively opening itself to investment. The chemical industry, in particular, is positioned for nearshoring-driven growth.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
